본문 바로가기
KERD
논문KCI 등재

Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines

전덕인|추일한|김문두|심세훈|박원명|Jeong Seok Seo|Young Sup Woo|Won Kim|Sung-Yong Park|Jung Goo Lee|Chan-Mo Yang|Bo-Hyun Yoon|Inki Sohn|Myung Hun Jung|정종현
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2023.02|Clinical Psychopharmacology and Neuroscience|제21권 제1호|pp. 32-48|DOI 10.9758/cpn.2023.21.1.32

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

GuidelineBipolar disorderAlgorithmPharmacotherapyKMAP-BP 2022

초록

The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) with other recently published guidelines for treating bipolar disorder. We reviewed a total of six recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2022 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy in a same degree for mania. However, the KMAP-BP 2022 recommended MS + AAP combination therapy for psychotic mania, mixed mania and psychotic depression as treatment of choice. Aripiprazole, quetiapine and olanzapine were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Some guideline suggested olanzapine is a second-line options during maintenance treatment, related to concern about long-term tolerability. Most guidelines advocated newer AAPs (asenapine, cariprazine, long-acting injectable risperidone, and aripiprazole once monthly) as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. KMAP-BP 2022 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2022, predominantly in the treatment of psychotic mania, mixed mania and psychotic depression.

Abstract

The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) with other recently published guidelines for treating bipolar disorder. We reviewed a total of six recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2022 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy in a same degree for mania. However, the KMAP-BP 2022 recommended MS + AAP combination therapy for psychotic mania, mixed mania and psychotic depression as treatment of choice. Aripiprazole, quetiapine and olanzapine were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Some guideline suggested olanzapine is a second-line options during maintenance treatment, related to concern about long-term tolerability. Most guidelines advocated newer AAPs (asenapine, cariprazine, long-acting injectable risperidone, and aripiprazole once monthly) as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. KMAP-BP 2022 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2022, predominantly in the treatment of psychotic mania, mixed mania and psychotic depression.

참고문헌 (77)

  1. Evidence-Based Medicine Working Group, "Evidence-based medicine. A new approach to teaching the practice of medicine", JAMA, 268, pp.2420~2425 (1992)
  2. Practice guideline for major depressive disorder in adults, "American Psychiatric Association", Am J Psychiatry, 150(4 Suppl), pp.1~26 (1993)
  3. Practice guideline for the treatment of patients with bipolar disorder, "American Psychiatric Association", Am J Psychiatry, 151(12 Suppl), pp.1~36 (1994)
  4. Sachs GS, "The expert consensus guideline series: medication treatment of bipolar disorder 2000", Postgrad Med, pp.1~104 (2000)
  5. Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 17, pp.149~173 (2003)
  6. Parker GB, "Is there consensus across international evidence-based guidelines for the management of bipolar disorder?", Acta Psychiatr Scand, 135, pp.515~526 (2017)
  7. Jon DI, "The Korean Medication Algorithm Project for Bipolar Disorder(KMAP-BP) : changes in preferred treatment strategies and medications over 16 years and five editions", Bipolar Disord, 22, pp.461~471 (2020)
  8. Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary", Clinical Psychopharmacology and Neuroscience, 19(4), pp.751~772 (2021), 대한정신약물학회[DOI]
  9. Young Sup Woo, "The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 20(1), pp.37~50 (2022), 대한정신약물학회[DOI]
  10. Jong Hyun Jeong, "Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 17(2), pp.155~169 (2019), 대한정신약물학회[DOI]
  11. The Executive Committee of Korean Medication Algorithm Project for Bipolar Disorder, "The Korean medication guideline for Bipolar Disorder 2002" (2002), Jungang Moonwhasa
  12. Jon DI, "Algorithm-driven treatment for bipolar disorder in Korea : clinical feasibility, efficacy, and safety", Int J Psychiatry Clin Pract, 13, pp.122~129 (2009)
  13. Jon DI, "Revised Korean Medication Algorithm for Bipolar Disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
  14. Shin YC, "Korean Medication Algorithm for Bipolar Disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
  15. Woo YS, "Korean Medication Algorithm Project for Bipolar Disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
  16. Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
  17. Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary", Clinical Psychopharmacology and Neuroscience, 20(4), pp.747~761 (2022), 대한정신약물학회[DOI]
  18. Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
  19. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
  20. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)recommendations for the management of patients with bipolar disorder with mixed presentations", Bipolar Disord, 23, pp.767~788 (2021)
  21. Fountoulakis KN, "The International College of Neuro-Psychopharmacology(CINP)Treatment Guidelines for Bipolar Disorder in Adults(CINP-BD-2017), part 3 : the clinical guidelines", Int J Neuropsychopharmacol, 20, pp.180~195 (2017)
  22. National Collaborating Centre for Mental Health, "National Institute for Health and Clinical Excellence: guidance. Bipolar disorder. The NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care", The British Psychological Society and The Royal College of Psychiatrists, ~ (2014)
  23. National Collaborating Centre for Mental Health, "National Institute for Health and Clinical Excellence: guidance. Bipolar disorder: assessment and management", The British Psychological Society and The Royal College of Psychiatrists, ~ (2018)
  24. Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 55, pp.7~117 (2021)
  25. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2009 on the treatment of acute mania", World J Biol Psychiatry, 10, pp.85~116 (2009)
  26. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2010 on the treatment of acute bipolar depression", World J Biol Psychiatry, 11, pp.81~109 (2010)
  27. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : update 2012 on the long-term treatment of bipolar disorder", World J Biol Psychiatry, 14, pp.154~219 (2013)
  28. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : acute and long-term treatment of mixed states in bipolar disorder", World J Biol Psychiatry, 19, pp.2~58 (2018)
  29. American Psychiatric Association, "Practice guideline for the treatment of patients with bipolar disorder(revision)", Am J Psychiatry, 159(4 Suppl), pp.1~50 (2002)
  30. Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : revised second edition--recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 23, pp.346~388 (2009)
  31. Sharma V, "Continuation and prophylactic treatment of bipolar disorder", Can J Psychiatry, 42(Suppl 2), pp.92S~100S (1997)
  32. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)guidelines for the management of patients with bipolar disorder : consensus and controversies", Bipolar Disord, 7(Suppl 3), pp.5~69 (2005)
  33. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)guidelines for the management of patients with bipolar disorder : update 2007", Bipolar Disord, 8, pp.721~739 (2006)
  34. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)collaborative update of CANMAT guidelines for the management of patients with bipolar disorder : update 2009", Bipolar Disord, 11, pp.225~255 (2009)
  35. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)collaborative update of CANMAT guidelines for the management of patients with bipolar disorder : update 2013", Bipolar Disord, 15, pp.1~44 (2013)
  36. National Collaborating Centre for Mental Health, "Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care" (2006), British Psychological Society
  37. Malhi GS, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
  38. Grunze H, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of bipolar disorders. Part I : treatment of bipolar depression", World J Biol Psychiatry, 3, pp.115~124 (2002)
  39. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders, part II : treatment of mania", World J Biol Psychiatry, 4, pp.5~13 (2003)
  40. Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders, part III : maintenance treatment", World J Biol Psychiatry, 5, pp.120~135 (2004)
  41. Davis DA, "Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines", CMAJ, 157, pp.408~416 (1997)
  42. Lin D, "Polytherapy in bipolar disorder", CNS Drugs, 20, pp.29~42 (2006)
  43. Ketter TA, "Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder", J Clin Psychiatry, 69(Suppl 5), pp.9~15 (2008)
  44. Bourin MS, "Lithium as add-on to quetiapine XR in adult patients with acute mania : a 6-week, multicenter, double-blind, randomized, placebo-controlled study", Int J Bipolar Disord, 2, pp.14~ (2014)
  45. Xu L, "Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania : a randomized controlled study in a Chinese population group", Neuropsychiatr Dis Treat, 11, pp.1265~1271 (2015)
  46. Ogawa Y, "Mood stabilizers and antipsychotics for acute mania : a systematic review and meta-analysis of combination", augmentation therapy versus monotherapy, 2014, pp.28, 989~1003
  47. In Hee Shim, "Predictors of a Shorter Time to Hospitalization in Patients with Bipolar Disorder: Medication during the Acute and Maintenance Phases and Other Clinical Factors", Clinical Psychopharmacology and Neuroscience, 15(3), pp.248~255 (2017), 대한정신약물학회[DOI]
  48. Calogero Crapanzano, "Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors", Clinical Psychopharmacology and Neuroscience, 20(3), pp.403~414 (2022), 대한정신약물학회[DOI]
  49. Hu C, "Trajectories of body mass index change in first episode of mania : 3-year data from the Systematic Treatment Optimization Program for Early Mania(STOP-EM)", J Affect Disord, 208, pp.291~297 (2017)
  50. Baldessarini RJ, "Factors associated with treatment nonadherence among US bipolar disorder patients", Hum Psychopharmacol, 23, pp.95~105 (2008)
  51. Cipriani A, "Comparative efficacy and acceptability of antimanic drugs in acute mania : a multiple-treatments meta-analysis", Lancet, 378, pp.1306~1315 (2011)
  52. Lindström L, "Maintenance therapy with second generation antipsychotics for bipolar disorder-a systematic review and meta-analysis", J Affect Disord, 213, pp.138~150 (2017)
  53. Reischies FM, "Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics", Pharmacopsychiatry, 35, pp.244~246 (2002)
  54. Mojtabai R, "National trends in psychotropic medication polypharmacy in office-based psychiatry", Arch Gen Psychiatry, 67, pp.26~36 (2010)
  55. Vieta E, "Pharmacological management of bipolar depression : acute treatment, maintenance, and prophylaxis", CNS Drugs, 27, pp.515~529 (2013)
  56. Sachs GS, "Effectiveness of adjunctive antidepressant treatment for bipolar depression", N Engl J Med, 356, pp.1711~1722 (2007)
  57. McGirr A, "Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression : a systematic review and meta-analysis of randomised placebo-controlled trials", Lancet Psychiatry, 3, pp.1138~1146 (2016)
  58. Hu Y, "Adjunctive antidepressants for the acute treatment of bipolar depression : a systematic review and meta-analysis", Psychiatry Res, 311, pp.114468~ (2022)
  59. Solmi M, "Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression : a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials", CNS Spectr, 21, pp.403~418 (2016)
  60. Cruz N, "Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression : a meta-analysis", Int J Neuropsychopharmacol, 13, pp.5~14 (2010)
  61. Selle V, "Treatments for acute bipolar depression : meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics", Pharmacopsychiatry, 47, pp.43~52 (2014)
  62. Cuomo A, "Drug safety evaluation of aripiprazole in bipolar disorder", Expert Opin Drug Saf, 18, pp.455~463 (2019)
  63. Fountoulakis KN, "A systematic review of the evidence on the treatment of rapid cycling bipolar disorder", Bipolar Disord, 15, pp.115~137 (2013)
  64. Young Sup Woo, "Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea", Clinical Psychopharmacology and Neuroscience, 15(2), pp.177~180 (2017), 대한정신약물학회[DOI]
  65. Kelly T, "The utility of low-dose aripiprazole for the treatment of bipolar II and bipolar NOS depression", J Clin Psychopharmacol, 37, pp.99~101 (2017)
  66. Calabrese JR, "Bipolar rapid cycling : focus on depression as its hallmark", J Clin Psychiatry, 62(Suppl 14), pp.34~41 (2001)
  67. Zupancic ML, "Role of atypical antipsychotics in rapid cycling bipolar disorder : a review of the literature", Ann Clin Psychiatry, 23, pp.141~149 (2011)
  68. Poo SX, "Atypical anti-psychotics in adult bipolar disorder : current evidence and updates in the NICE guidelines", Psychiatr Danub, 26(Suppl 1), pp.322~329 (2014)
  69. Goldberg JF, "The American Society of Clinical Psychopharmacology survey of psychopharmacologists’ practice patterns for the treatment of mood disorders", Depress Anxiety, 32, pp.605~613 (2015)
  70. Roosen L, "Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review", J Affect Disord, 311, pp.69~77 (2022)
  71. Quiroz JA, "Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder", Biol Psychiatry, 68, pp.156~162 (2010)
  72. Vieta E, "A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder", Eur Neuropsychopharmacol, 22, pp.825~835 (2012)
  73. Chan HW, "Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder : a 1-year retrospective cohort study", J Affect Disord, 205, pp.360~364 (2016)
  74. Kishi T, "Mood stabilizers and", or antipsychotics for bipolar disorder in the maintenance phase : a systematic review and network meta-analysis of randomized controlled trials, 2021, pp.26, 4146~4157
  75. Pacchiarotti I, "Long-acting injectable antipsychotics(LAIs)for maintenance treatment of bipolar and schizoaffective disorders : a systematic review", Eur Neuropsychopharmacol, 29, pp.457~470 (2019)
  76. Calabrese JR, "Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder : A double-blind, placebo-controlled, 52-week randomized withdrawal study", J Clin Psychiatry, 78, pp.324~331 (2017)
  77. Calabrese JR, "Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder", J Affect Disord, 227, pp.649~656 (2018)

관련 논문AI추천

Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines이정구, 전덕인, Bo-Hyun Yoon, Hoo-Rim Song, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2019 · 제17권 제2호Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary김문두, 박원명, 전덕인, 정명훈, 정종현, 추일한, Bo-Hyun Yoon, Chan-Mo Yang, Inki Sohn, Jeong Seok Seo, Jung Goo Lee, Se-Hoon Shim, Sung-Yong Park, Won Kim, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제4호한국형 양극성 장애 약물치료 알고리듬 2022: 총론김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호한국형 양극성 장애 약물치료 알고리듬 2022: 유지치료김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제3호한국형 양극성 장애 약물치료 알고리듬 2022: 조증 삽화김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision송후림, Bo-Hyun Yoon, Duk-In Jon, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Jung Goo Lee, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제4호

이 간행물의 다른 논문 (20건)

COVID-19 Impact on the Italian Community-based System of Mental Health Care: Reflections and Lessons Learned for the FutureEdoardo Bruno, Eleonora Vai, Andrea Amerio, Anna Odone, Seyyed Nassir Ghaemi, Mario Amore, Gianluca Serafini, Andrea Aguglia, Domenico De Berardis, Andrea Escelsior, Alessandra Costanzapp. 2-9The Clinical Observation of Inflammation Theory for Depression: The Initiative of the Formosa Long COVID Multicenter Study (FOCuS)Ching-Fang Sun, Shao-Cheng Wang, Chih-Sung Liang, Senthil Kumaran Satyanarayanan, Kuan-Pin Su, Kai-Jie Yang, Che-Sheng Chu, Chia-Chun Yang, Shu-Tsen Liu, Sheng-Che Lin, Jane Pei-Chen Changpp. 10-18Electroceutical and Bioelectric Therapy: Its Advantages and LimitationsBori Jung, Chaeyeon Yang, Seung-Hwan Leepp. 19-31Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the LiteratureStefano Damiani, Chiara Amendola, Ilaria Casolaro, Calogero Crapanzanopp. 49-56Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia정영철, Anna Jo, Jae-Min Kim, Bong Ju Lee, Sung-Wan Kim, Eun-Jin Cheon, Seunghee Wonpp. 57-67
원문 보기